STOCK TITAN
  1. Home
  2. News
  3. ILMN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated news page for Illumina (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.

News
Engineering a Cool Career in Biotech - and Volunteering Along the Way
Rhea-AI Summary
Illumina employee Allie Duchnak, a Staff Engineer, shares her experience working on highly confidential projects at Illumina's San Diego headquarters. She discusses building test beds for components that may become part of a sequencer and her involvement in Illumina's CSR initiative. Duchnak studied nanoengineering at the University of California, San Diego, and transitioned to bioengineering and biology. She continues to volunteer through internal opportunities at Illumina, aiming to reach 5 million STEM learners by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
Rhea-AI Summary
A recent literature review published in the Nature journal Genomic Medicine supports the use of short-read genomic sequencing (GS) as the first-line standard of care for diagnosing rare genetic conditions in pediatric patients. The study conducted by the Medical Genome Initiative (MGI) found that GS reduces diagnostic time, with an average diagnostic yield of 45% for first-tier genomic sequencing. The evidence shows that genomic sequencing should be the initial genetic test for patients in intensive care units and those with unexplained conditions. While genomic sequencing offers high diagnostic yields and rapid results, more research is needed in outpatient settings. The study highlights the cost-effectiveness of GS due to recent reductions in sequencing costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Illumina's planned divestment of GRAIL approved by the European Commission
Rhea-AI Summary
Illumina, Inc. has received approval from the European Commission for its divestment plan for GRAIL, representing a significant step in the process. The company aims to finalize terms by the end of the second quarter of 2024, exploring trade sale or capital markets options. Illumina may need to fund GRAIL with approximately $1 billion for a capital markets transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
News
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
Rhea-AI Summary
Summit Therapeutics Inc. (SMMT) appoints Mostafa Ronaghi, PhD, to its Board of Directors. Dr. Ronaghi's extensive experience in genomics and sequencing from Illumina and GRAIL will enhance Summit's executive team. His background in founding successful biotech companies brings valuable expertise to Summit's mission of advancing patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
management
-
News
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Rhea-AI Summary
Illumina appoints Ankur Dhingra as CFO and Jakob Wedel as Chief Strategy and Corporate Development Officer. Joydeep Goswami to serve as advisor till June 30. Illumina reaffirms Q1 2024 and full-year 2024 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
management
-
News
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer
Rhea-AI Summary
Whole-genome sequencing (WGS) is gaining momentum in precision oncology, particularly in hematologic and pediatric cancers. Illumina's Global Medical Director of Oncology highlights the significance of WGS in accurate diagnosis, classification, and therapy guidance for complex cancers. Recent studies showcase WGS's superiority over standard testing methods, emphasizing its potential in revolutionizing cancer care globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
News
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
Rhea-AI Summary
Illumina, Inc. (ILMN) will release its first quarter 2024 results on May 2, 2024, followed by a conference call with CEO Jacob Thaysen and CFO Joydeep Goswami to discuss financial and operating results. The call will be accessible through Illumina's website or by phone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
earnings
-
News
Giving Students a New Window on Genomic Technologies
Rhea-AI Summary
Illumina Genomic Discoveries partners with high school students to enhance genomic learning experiences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News
GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
Rhea-AI Summary
GRAIL, to present new data on the clinical utility of its Methylation Platform and the impact of multi-cancer early detection testing at the AACR Annual Meeting. The data highlights the potential value of repeat screening for significant cancers and precision oncology, showcasing GRAIL's commitment to transforming cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
none
News
A Biobank for the Americas and a Genomics Lab Power Precision Health for All
Rhea-AI Summary
Illumina collaborates with Galatea Bio to advance precision medicine for underserved populations through genomic datasets enriched by Carlos D. Bustamante's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
Stock ILMN logo
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

#529 Ranked by Market Cap
#4729 Ranked by Stock Gains
N/A Ranked by Dividends

ILMN Stock Data

20.24B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
San Diego

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.